West Nile Disease

西尼罗河病在美国已经发展成为一个主要的蚊子传播的健康问题。目前还没有有效的治疗方法。动物模型表明免疫血清可能是有益的。与NIAID：协作抗病毒研究小组合作制定了一项国家方案，以研究从以色列获得的高滴度免疫球蛋白与适当安慰剂的疗效。该研究是随机和双盲的。它已经在美国和加拿大的60个中心开放，包括临床中心。迄今为止，已有39名患者入组，其中包括临床中心的两名患者。该协议是校内外合作的典范，以应对新出现的感染的挑战。由于2005年美国病例的缺乏，这项研究受到了阻碍，但正在评估观察性数据、随访和药代动力学。

West Nile Disease has developed as a major mosquito borne health problem in the United States. No therapy is known to be effective. Animal models suggest that immune serum may be beneficial. A national protocol has been developed in collaboration with the NIAID: Collaborative Antiviral Study Group to study the efficacy of high titer immunoglobulin, obtained from Israel, compared to appropriate placebos. The study is randomized and double blinded. It has opened at 60 centers in the United States and Canada including the Clinical Center. Thirty-nine patients have been enrolled to date, including two at the Clinical Center. This protocol is a model for intramural-extramural collaboration to meet the challenge of a new, emerging infection. This study has been hampered by the dearth of US cases in 2005, but observational data, follow up, and pharmacokinetics are being assessed.